2019
August 5, 2019 | Antidote Therapeutics Progresses Optimization of the Nicotine-degrading Enzyme, NicA2, for Potential Use in Treating Nicotine Addiction
February 13, 2019 | Washington Business Journal, Gaithersburg biotech is raising millions to treat nicotine-related diseases — and help smokers quit
Matt Kalnik wants to make smoking less addictive. His clinical-stage company, Gaithersburg-based Antidote Therapeutics Inc., is developing a drug that would diminish the effects of nicotine in the body — to both treat diseases worsened by nicotine and help smokers quit. Read full story
2018
October 31, 2018 | Selected a Top 500 startup from 4,500 contenders by Hello Tomorrow’s Global Challenge, a renowned deep tech startup competition intended to propel innovation from lab to market to help solve the world’s toughest challenges.
September 5, 2018 | Antidote Therapeutics Receives Orphan Drug Designation for ATI-1013 for the Treatment of Buerger’s Disease
March 2018 | Pre-clinical Research services agreement to evaluate ATI-1013’s efficacy in reducing nicotine’s cardiovascular effects in rats
January 2018 | Sponsored Research and Option agreement with The University of Texas, Austin for optimization of nicotine degrading enzymes
2017
December 2017 | Entered commercial evaluation agreement with Clearview Healthcare Partners
August 2017 | Investment from Novartis Venture Funds
July 2107 | Entered manufacturing services agreement for ATI-1013
June 2017 | Investment from Maryland’s TEDCO
March 2017 | Award of a Phase 1 Small Business Innovative Research grant from NIDA for nicotine-degrading enzymes
February 2017 | National stage patent application filings for “Nicotine-degrading enzymes for treating nicotine addiction and nicotine poisoning”
2015
November 2015 | Sponsored Research and Option Agreement with The Scripps Research Institute for in vivo evaluation of nicotine degrading enzymes
August 2015 | Collaboration and Option Agreement with Blink Biomedical for discovery of antibodies (IgG) against nicotine
June 2015 | Began enrollment in ATI-1501 clinical research study
2014
December 2014 | Entered multiple Sponsored Research and Option Agreements with Strategic Alliance collaborative partners: The University of Minnesota and Minneapolis Medical Research Foundation, The Scripps Research Institute, The University of California at San Diego, BliNK Biomedical, Cato Research, and BioFactura.
September 2014 | Awarded $8.5 million Strategic Alliance grant for “Lead Optimization and Preclinical Development of Human Nicotine-Specific mAbs” from the National Institute on Drug Abuse (NIDA)
